Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials

by Janet B. McGill
Published 2012-08-01

Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence

by Janet B McGill
Published 2010-05-01

Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium‐Glucose Cotransporter‐2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes

by Yan Xie, Benjamin Bowe, Andrew K. Gibson, Janet B. McGill, Geetha Maddukuri, Ziyad Al‐Aly
Published 2021-06-01

Enhancing the get healthy information and coaching service for Aboriginal adults: evaluation of the process and impact of the program

by E. Quinn, B. J. O’Hara, N. Ahmed, S. Winch, B. McGill, D. Banovic, M. Maxwell, C. Rissel
Published 2017-09-01

Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness

by Janet B. McGill, Mariko Johnson, Stacy Hurst, William T. Cade, Kevin E. Yarasheski, Richard E. Ostlund, Kenneth B. Schechtman, Babak Razani, Michael B. Kastan, Donald A. McClain, Lisa de las Fuentes, Victor G. Davila-Roman, Daniel S. Ory, Samuel A. Wickline, Clay F. Semenkovich
Published 2019-07-01

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

by Barry M Brenner, Mark E Cooper, Dick de Zeeuw, Jean-Pierre Grunfeld, William F Keane, Kiyoshi Kurokawa, Janet B McGill, William E Mitch, Hans Henrik Parving, Guiseppe Remuzzi, Arthur B Ribeiro, Mark D Schluchter, Duane Snavely, Zhongxin Zhang, Roger Simpson, Denise Ramjit, Shahnaz Shahinfar, RENAAL Study Investigators
Published 2000-12-01